Alan Cu Chiam, MD
Internal Medicine · Atlanta, GANPI 1912069022
Payments from drug & device makers
Across 155 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AbbVie$333
- AstraZeneca$222
- Kowa Pharmaceuticals America, Inc.$215
- Abbott$174
- Gilead$150
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,351100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $1,028 |
| AbbVie | 19 | $333 |
| AstraZeneca | 6 | $222 |
| Kowa Pharmaceuticals America, Inc. | 12 | $215 |
| Abbott | 5 | $174 |
| Gilead | 7 | $150 |
| Johnson & Johnson | 5 | $96 |
| Lilly USA, LLC | 6 | $95 |
| Pfizer | 5 | $92 |
| Vanda Pharmaceuticals Inc. | 4 | $92 |
| Medtronic | 1 | $89 |
| Novo Nordisk | 4 | $68 |
| Astellas Pharma US Inc | 3 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $65 |
| Sanofi Pasteur Inc. | 2 | $61 |
| Amgen | 4 | $58 |
| Boehringer Ingelheim | 3 | $51 |
| Merck | 3 | $47 |
| Baxter Healthcare | 1 | $44 |
| Novartis | 2 | $41 |
| Exact Sciences | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 3 | $38 |
| Lundbeck LLC | 1 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,351 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 167 | $120,802 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 20 | $86,646 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 21 | $81,933 |
| EliquisApixaban | 53 | $57,488 |
| JardianceEmpagliflozin | 41 | $56,178 |
| OzempicSemaglutide | 47 | $51,285 |
| MyrbetriqMirabegron | 37 | $32,630 |
| FarxigaDapagliflozin Propanediol | 20 | $21,161 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $20,052 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 467 | $13,356 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $12,705 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $12,459 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,032 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,872 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya, Biktarvy | $150 | $168,57941 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,028 | $145,966214 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $51 | $76,23072 claims |
| PfizerEliquis | $92 | $57,48853 claims |
| Novo NordiskOzempic | $68 | $51,28547 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $32,63037 claims |
| AstraZenecaFarxiga, Symbicort | $222 | $30,03349 claims |
| MerckJanumet | $47 | $11,03215 claims |
| Sanofi-aventis U.S. LLCLantus | $38 | $1,95129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Atlanta
- Kimball JohnsonAtlanta$51.1M
- Robert Springer IiiAtlanta$5.3M
- Paulina Rebolledo EsteinouAtlanta$2.1M
- Courtney SheltonAtlanta$1.2M
- Melanie ThompsonAtlanta$1.1M
- Tracey HenryAtlanta$305K
- David WatsonAtlanta$286K
- Priscilla Igho-PemuAtlanta$269K
- Robert HerreraAtlanta$261K
- Syed RahmanAtlanta$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.